Off-Label Uses of Anti-TNF Therapy in Three Frequent Disorders: Behçet’s Disease, Sarcoidosis, and Noninfectious Uveitis

Table 1

Characteristics of the different anti-TNF agents.

	Infliximab	Etanercept	Adalimumab	Certolizumab pegol	Golimumab
Type	Monoclonal antibody against TNF-𝛼	TNF soluble receptor	Monoclonal antibody against TNF-𝛼	Monoclonal antibody against TNF-𝛼	Monoclonal antibody against TNF-𝛼
Composition	Chimeric antibody	Recombinant fusion protein	Recombinant monoclonal antibody	Monoclonal antibody	Monoclonal antibody
Origin	Human and murine	Human	Human	Human	Human
Mechanism of action	Binding to soluble and cell-bound TNF-𝛼	Binding to soluble TNF-𝛼 and TNF-𝛽	Binding to soluble and cell-bound TNF-𝛼	Binding to soluble and cell-bound TNF-𝛼	Binding to soluble and cell-bound TNF-𝛼
Dose	3–5 mg/kg at weeks 0, 2, and 6; then, every 4–8 weeks	25–50 mg once or twice a week	40 mg every other week	400 mg every other week (maintenance every 4 weeks can be considered)	50 mg once monthly
Administration route	Intravenous	Subcutaneous	Subcutaneous	Subcutaneous	Subcutaneous